Clinical Trials
19
Trial Phases
4 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (19 trials with phase data)• Click on a phase to view related trials
Evaluation of the Bioequivalence of Sprinkle and Capsule Formulations of Lubiprostone, as Compared to Placebo
- Conditions
- Chronic Idiopathic Constipation
- Interventions
- Drug: Placebo
- First Posted Date
- 2017-03-31
- Last Posted Date
- 2020-01-14
- Lead Sponsor
- Sucampo Pharma Americas, LLC
- Target Recruit Count
- 552
- Registration Number
- NCT03097861
- Locations
- 🇺🇸
Investigative Site, Richmond, Virginia, United States
🇺🇸Investigative Sitee, High Point, North Carolina, United States
🇺🇸Investigative Site 2, Jackson, Tennessee, United States
Comparative Pharmacokinetics and Food-Effect Bioavailability of Lubiprostone Sprinkle in Healthy Volunteers
- Conditions
- Healthy Volunteers
- First Posted Date
- 2017-01-05
- Last Posted Date
- 2020-03-09
- Lead Sponsor
- Sucampo Pharma Americas, LLC
- Target Recruit Count
- 49
- Registration Number
- NCT03010631
- Locations
- 🇺🇸
ICON, San Antonio, Texas, United States
Evaluation of the Safety of Lubiprostone in Pediatric Participants Aged ≥ 6 Years to < 18 Years With Functional Constipation
- First Posted Date
- 2016-05-10
- Last Posted Date
- 2020-05-15
- Lead Sponsor
- Sucampo Pharma Americas, LLC
- Target Recruit Count
- 87
- Registration Number
- NCT02766777
- Locations
- 🇺🇸
Northwest Arkansas Pediatric Clinic, Fayetteville, Arkansas, United States
🇺🇸Methodist Medical Center, Peoria, Illinois, United States
🇺🇸Willis-Knighton Physician Network, Shreveport, Louisiana, United States
Evaluation of the Efficacy and Safety of Lubiprostone in Adults With Mixed or Unsubtyped Irritable Bowel Syndrome
- First Posted Date
- 2015-09-09
- Last Posted Date
- 2019-12-27
- Lead Sponsor
- Sucampo Pharma Americas, LLC
- Target Recruit Count
- 71
- Registration Number
- NCT02544152
- Locations
- 🇺🇸
E Squared Research, Inc., Huntsville, Alabama, United States
🇺🇸Arkansas Gastroenterology, North Little Rock, Arkansas, United States
🇺🇸GW Research Inc., Chula Vista, California, United States
Cobiprostone for the Prevention of Oral Mucositis in Subjects With Head and Neck Cancer Receiving Concurrent Radiation and Chemotherapy
- Conditions
- Oral Mucositis
- Interventions
- Drug: PlaceboDrug: Standard Care - ChemotherapyRadiation: Standard Care - Radiation
- First Posted Date
- 2015-09-04
- Last Posted Date
- 2019-12-02
- Lead Sponsor
- Sucampo Pharma Americas, LLC
- Target Recruit Count
- 47
- Registration Number
- NCT02542215
- Locations
- 🇺🇸
Investigational Site, Madison, Wisconsin, United States
- Prev
- 1
- 2
- 3
- 4
- Next